Skip to main content

Adnexal Mass

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Natera
NateraAUSTIN, TX
1 program
Natera Ovarian Cancer Detection AssayN/A1 trial
Active Trials
NCT03485651Terminated12Est. Dec 2019
Lantheus Medical Imaging
1 program
Perflutren Lipid MicrospheresPHASE_11 trial
Active Trials
NCT03297112Completed12Est. Sep 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Lantheus Medical ImagingPerflutren Lipid Microspheres
NateraNatera Ovarian Cancer Detection Assay

Clinical Trials (2)

Total enrollment: 24 patients across 2 trials

NCT03297112Lantheus Medical ImagingPerflutren Lipid Microspheres

Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery

Start: Aug 2017Est. completion: Sep 201812 patients
Phase 1Completed
NCT03485651NateraNatera Ovarian Cancer Detection Assay

Natera Ovarian Cancer Detection Assay

Start: Dec 2017Est. completion: Dec 201912 patients
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.